ARIAD Announces Launch of Inaugural ALK+ Day During Lung Cancer Awareness Month
November 14 2016 - 7:35AM
Business Wire
Collaboration with patient advocacy community
to raise awareness about the recent progress in ALK+ non-small cell
lung cancer research
Launch of patient and caregiver website,
www.livingwithALK.com
In recognition of this month’s Lung Cancer Awareness Month,
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the
launch of an inaugural awareness day for anaplastic lymphoma kinase
positive (ALK+) metastatic non-small cell lung cancer (NSCLC)
patients and their care partners. The awareness day is the first of
its kind to specifically focus on ALK+ NSCLC and will be held on
November 15th and subsequently on the third Tuesday of each
November.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20161114005418/en/
The inaugural ALK+ Day is November 15,
during Lung Cancer Awareness Month. (Photo: Business Wire)
“This year we’re recognizing our 25 year anniversary as a
company and we are extremely proud of our research efforts for rare
cancers. This inaugural ALK+ Day, a collaborative engagement with
the lung cancer patient advocacy community, has the goal to place
progress made in the ALK+ NSCLC space within the context of
advances made in non-small cell lung cancer research,” stated
Timothy P. Clackson, Ph.D., president of research and development
and chief scientific officer at ARIAD. “As we engage with the lung
cancer community we aim to help raise awareness about ALK+ NSCLC
and encourage others to join the conversation about the R&D
progress in this rare cancer space, as well as the importance of
mutation testing.”
This month, ARIAD seeks to support patient education and
community, while also advancing innovative science focused on rare
cancers. Through its collaboration with the Lung Cancer Foundation
of America (LCFA), the community is encouraged to talk about “The
Little Things” that lung cancer patients are thankful for, that
their lungs allow them to do, using the social media hashtag
#LittleThingsLCFA during the month of November.
“We are excited to work with ARIAD on building awareness about
ALK+ non-small cell lung cancer during Lung Cancer Awareness Month
in order to highlight the progress and work still-to-be-done in
battling lung cancer. Our mission is the dramatic improvement in
survivorship of lung cancer patients through the funding of
transformative science, with the ultimate goal of curing the
disease,” said Kim Norris, president and co-founder of the Lung
Cancer Foundation of America.
As part of its ongoing commitment to patients, ARIAD has also
launched the Living with ALK website to help patients and
caregivers access support, resources, and information for living
with ALK+ non-small cell lung cancer.
About ALK+ NSCLC
Non-small cell lung cancer (NSCLC) is the most common form of
lung cancer, accounting for approximately 85 percent of the
estimated 228,190 new cases of lung cancer diagnosed each year in
the United States, according to the American Cancer Society.
Anaplastic lymphoma kinase (ALK) was first identified as a
chromosomal rearrangement in anaplastic large-cell lymphoma (ALCL).
Genetic studies indicate that chromosomal rearrangements in ALK are
key drivers in a subset of NSCLC patients as well. Approximately
three to eight percent of patients with NSCLC have a rearrangement
in the ALK gene.
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts, is focused on discovering, developing and
commercializing precision therapies for patients with rare cancers.
ARIAD is working on new medicines to advance the treatment of rare
forms of chronic and acute leukemia, lung cancer and other rare
cancers. ARIAD utilizes computational and structural approaches to
design small-molecule drugs that overcome resistance to existing
cancer medicines. For additional information, visit
http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).
Forward-Looking Statements
This press release contains forward-looking statements, each of
which are qualified in their entirety by this cautionary statement.
Any statements contained herein which do not describe historical
facts, including, but not limited to the statements related to our
research efforts, our goals for increasing ALK+ NSCLC awareness,
and our education, awareness and community programs, are
forward-looking statements that are based on management’s
expectations and are subject to certain factors, risks and
uncertainties that may cause actual results, outcome of events,
timing and performance to differ materially from those expressed or
implied by such statements. These factors, risks and uncertainties
include, but are not limited to, our ability to successfully
commercialize and generate profits from sales of our products; our
ability to meet anticipated clinical trial commencement, enrollment
and completion dates and regulatory filing dates for our products
and product candidates and to move new development candidates into
the clinic; our ability to execute on our key corporate
initiatives; regulatory developments and safety issues, including
difficulties or delays in obtaining regulatory and pricing and
reimbursement approvals to market our products; competition from
alternative therapies; our reliance on the performance of
third-party manufacturers, specialty pharmacies, distributors and
other collaborators for the supply, distribution, development
and/or commercialization of our products and product candidates;
the occurrence of adverse safety events with our products and
product candidates; the costs associated with our research,
development, manufacturing, commercialization and other activities;
the conduct, timing and results of preclinical and clinical studies
of our products and product candidates, including that preclinical
data and early-stage clinical data may not be replicated in
later-stage clinical studies; the adequacy of our capital resources
and the availability of additional funding; the ability to satisfy
our contractual obligations, including under our leases,
convertible debt and royalty financing agreements; patent
protection and third-party intellectual property claims; litigation
and government investigations; our operations in foreign countries
with or through third parties; risks related to key employees,
markets, economic conditions, health care reform, prices and
reimbursement rates; and other risk factors detailed in our public
filings with the U.S. Securities and Exchange Commission, including
our most recent Annual Report on Form 10-K and subsequent Quarterly
Reports on Form 10-Q. Except as otherwise noted, these
forward-looking statements speak only as of the date of this press
release and we undertake no obligation to update or revise any of
these statements to reflect events or circumstances occurring after
this press release. We caution investors not to place considerable
reliance on the forward-looking statements contained in this press
release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161114005418/en/
ARIAD Pharmaceuticals, Inc.For InvestorsJennifer
Robinson, 617-621-2286Jennifer.Robinson@ariad.comorFor
MediaLiza Heapes, 617-621-2315Liza.heapes@ariad.com
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Sep 2023 to Sep 2024